The coronary sinus: A safe and effective route for percutaneous myoblast transplantation  by Brasselet, Camille et al.
JACC March 19,2003 ABSTRACTS - Angiography & Interventional Cardiology 67A 
POSTER SESSION 
1176 Percutaneous Intervention: Stem Cells 
and Adjunctive Antithrombotic Therapy 
Tuesday, April 01, 2003, Noon-2:00 p.m. 
McCormick Place, Hall A 
Presentation Hour: Noon-l :00 p.m. 
1176-173 Mesenchymal Stromal Cell Transplantation Contributes 
to Collateral Response in Tissue lschemia Through 
Release of Arteriogenic Cytokines 
Tim D. Kinnaird Eugenlo Stabile, Mary Susan Burnett, Matie Shou, Yi Fu Zhou, Richard 
Baffour. Cheol Whan Lee. Shmuel Fuchs. Stephen E. Erxitein. Cardiovascular Research 
institute, Washington. DC 
Background: Mesenchymal stromal cell (MSC’s) transplantation is reported to contribute 
to angiogenesis through cell donation to new vessel formation. However, the humoral 
contribution of MSC’s to collateral response is less well characterized. Methods and 
Results: Murine MSC’s were purified usmg double magnetic bead separation of cultured 
bone marrow. Flow cytometry confirmed absence of CD34, CD45, CD31 and CD1 17 sur- 
face markers. and the presence of SH2 and Sea-1 surface markers. Conditioned media 
(CM) was collected after 72 hours of MSC culture. Using ELISA, we demonstrated 
release of: VEGF (375 pglmg protein in normoxia vs 698 pg/mg protein in 1% hypoxia, 
pcO.Ol), bFGF (2320pgImg vs 3970 pg/mg, p<O.O5), placental growth factor (4lOpg/mg 
vs 434pg/mg. p=NS) and MCP-1 (262 pg/mg vs 109 pglmg, p=NS). lmmunoblottlng of 
MSC protein extracts established the presence of metalloproteinase-9, angiopoetin-1 
and angiopoetin-2. CM enhanced proliferation of endothellal cells by 92% and of smooth 
muscle cells by 74%, and increased tube-formation in a dose dependant manner. 10mgl 
ml of anti-VEGF antibody only partially attenuated these effects (40% reduction in prolif- 
eration, no effect on tube formation). Balb/C mice (n=8) underwent distal femoral artery 
ligation; 24 hours later 5x10’ MSCs were injected into the adductor muscle. Compared to 
controls injected with media alone @=a). foot perfusion in MSC-treated mice increased 
by 63% at day 7 and by 67% at day 10 (p=O.O2). MSC transplantation improved limb 
function (ambulatory score 1.25 vs 0.5, p<O.O5). lessened limb ischemia (Ischemic score 
1.0 vs 2.75, ~~0.05) and reduced the incidence of auto-amputation (13% YS 50%) com- 
pared to controls. Conclusions: Injection of mesenchymal stromal cells into the ischemic 
hindlimb contributes to collateral responses through release of arteriogenic cytokines. 
1176-174 Percutaneous Endocardial Versus Selective Coronary 
Venous Cellular Delivery: Comparisons of Transplant 
Efficiency, Distribution, and Efficacy in Reducing Infarct 
Size and Improving Myocardial Function 
ErikT. Price Fumiaki Ikeno, Ralph C. Fenn, Pauline Chu, Jennifer K. Lyons, Peter J. -* 
Fitzgerald, Alan C. Yeung, Paul G. Yock. Mehrdad Rezaee, Stanford University Medical 
Center, Stanford, CA 
Background: Cellular transplantation is an emerging option for the treatment of ischemic 
cardiomyopathy. Percutaneous endocardial delivery (PED) and percutaneous coronary 
venous delivery (PCVD) offer potential advantages in safety, transplant efficiency, and 
targeted distribution for presewabon of myocardium. 
Methods: A total of 22 swine were studied: 6 PED and 4 PCVD for acute feasibility arm; 
and 4 PED, 4 PCVD, and 4 combined controls for chronic efficacy arm (LAD infarct by 
balloon occlusion). Porcine fibroblasts labeled with iron nano-particles were used for 
transplantation. Between 2-2.5xlO”cells were Injected into the infarct area either by PED 
using a BioCardiaTM hellcal infusion catheter, or by PCVD using a single high-pressure 
(100-200 mmHg) injection through a balloon-tipped catheter in the anterior interventricu- 
lar vein (AIV). Ejection fraction (EF) was measured at infarct induction (day 0), cell deliv- 
ery (day 7), and sacrifice (day 28). HorIzontat cross-sections of the left ventricle were 
stained with tetrazollum for infarct size, then with H&E and Prussian Blue for cell Identifi- 
cation. A linear computational model was used to estimate transplant efficiency. 
Results: Acute studies demonstrated safe, targeted transplantation using both modak- 
ties. In infarcted animals, PED and PCVD resulted in 17.3 + 24.3% and 15.7 f 11.6% of 
fibroblasts identified after 21 days. PED resulted in 98.4% of cells in the anteroseptal 
walls, with 95.8% localized to the endocardlal half, at an average depth of 3.4 + 3.9 mm. 
PCVD resulted in 97.6% of cells in the anteroseptal walls, a radial 21.8 f 7.9 mm from 
the AIV, with 60.1% localized to the endocardial half. With both modalities >96.0% of 
cells were within 5 mm of the Infarct zone. Both PED and PCVD trended in reduced inf- 
arct size compared to the controls (3.9 * 1.6 and 7.9 * 6.0, vs. 13.9 f 10.8, ~~0.12 and 
p=O.37 respectively), and improved EF (26.0 * 3.2 and 26.8 * 12.6 vs. 17.0 f 9.8, ~~0.13 
and p=O.27 respectively). 
Conclusions PED and PCVD provide comparable efficiency and targeted distribution. 
As anticipated, PCVD provides regional delivery, and PED a nwre local distribution. 
Studies are underway to further establish the efficacy of both modalities. 
1176-l 75 Catheter-Based Percutaneous Cellular 
Cardiomyoplasty Using Allogeneic Bone Marrow 
Derived Mesenchymal Stem Cells 
Marcus E. St. John Jinsheng Xie, Alan W. Heldman, Garrick C. Stewart, Stephen M. 
Cattaneo, David J. Caparrelli, William A. Baumgartner, Bradley J. Martin, Joshua M. 
Hare, Johns Hopkins Medical Institutions, Baltimore, MD, Osiris Therapeutics, Inc, 
Baltimore, MD 
Backgrounct Bone marrow derived mesenchymal stem cells (MSCs) administered by 
direct injection into a myocardial infarct (Ml) improve ventricular remodeling and global 
function in both large and small animal models. In order to demonstrate therapeutic appli- 
cability without need for surgery. we tested the hypothesis that MSCs delivered percuta- 
neously via catheter successfully engraft, migrate throughout a region of MI. and 
demonstrate evidence of myocyte differentiatmn in pigs. Methods: MI was produced by 
l-hour occlusion of the left anterior descending artery in domestic swne (weight 30. 
45kg). Three days later either 200 million Dil and DAPI-labeled allogeneic porcine MSCs 
or vehicle alone (randomly assigned; total n=9) were injected into the LV (lo-12 sites in 
the endocardium within the infarct zone) via a helical needle infusion catheter advanced 
through a deflectable guide catheter (BioCardia, Inc, CA). Results: Animals were eutha- 
nized between 2 to 8 weeks after injection. Pathology revealed transmural anteroseptal 
infarcts. MSC engraftment was observed in all treated animals, with transmural migration 
of implanted cells from endocardium to epicardium. MSCs were found associated with 
blood vessel walls and co-stained for factor VIII, consistent with neoangiogenesls. Trans- 
planted MSCs expressed muscle specific proteins including phospholamban, myosin 
heavy chain and alpha-actinin, which were not present before implantation, suggesting 
myogenic differentiation. Implanted MSCs were not found in regions of myocardium 
remote from the injection site, or systemically. There was no evidence of immunorejec- 
tion. No deaths, perforations or arrhythmias resulted from the catheterization or In@- 
tions. Conclusions MSCs can be successfully delivered via percutaneous catheter. 
Transplanted cells engraft, migrate transmurally, express myocyte phenotypic markers 
and may participate in neoangenesis. We conclude that catheter-based delivery of allo- 
geneic MSCs is both safe and effective and will facilitate practical application of stem cell 
technology !n the treatment of Ml and potentially other cardlomyopathic processes. 
1176-176 Safety of Autologous Bone Marrow Cell Injection in 
Humans With Severe lschemic Heart Failure 
Hans F. Dohmann. Emerson C. Perin, Andre Luiz S. Sousa, Radovan Borojevic, Antonio 
C. Catvalho, Isabel Rossi, Suzana A. Silva, Robeno Esporcatte. Guilherme V. Silva, 
Hans J. Dohmann, Fernando Rangel, James T. WilIerson. Texas Heart Institute, 
Houston, TX, Hospital Procardiaco, RIO de Janeiro, Brazil 
Background Severe ischemic heart failure (HF) in patients not amenable to revascular- 
ization carries a high mortakty. Treatment of this high risk gorup witn injection of myo- 
blasts revealed a high incidence of post-procedural malignant ventricular arrhythmcas. 
We evaluated the safety of transendocardial (TE) injections of bone marrow mononu- 
clear cells (BMNC) to treat pts with severe HF. Methods Fourteen pts (60 * 10 yrs, 12 
males) with refractory symptoms (CCSINYHA Ill-IV), LV dysfunction (EF 19 * 10 %) 
were included in the study. Bone marrow (5Oml) was aspirated and EMNCs were iso- 
lated. TE injections (15*2 sites, 0.2~~) were performed using the Myo-Star catheter 
(NOGA, B~osense). Pts were evaluated for post-procedural in-hospital events and 24h- 
Halter was peltormed as well as serial echocardiograms, cardiac enzymes and C- reac- 
tive protein (CRP) at baseline, 6h. 12h, 24h and 48 hours. Eight wks follow-up included 
24h-Holler and CRP levels. Student’s T-test was used for comparison. 
Results No in-hospital major events were observed. Minor events Included transient 
hypotension with pulmonary congestion (n=l) and frequent PVCs (n=l) on day 1. CK-MB 
did not increase (peak 3.0tl.5 mcg/l, normal ~5 mcg/l) and Troponin I was mildly ele- 
vated (peak 1.0+0.7 nglml, normal < 0.4 nglml).CRP levels increased from 0.955 0.68 to 
2.0 t 0.70 mg/dl (p=O.O03) at 24h and decreased at 8 weeks (1.27+1 1 mg/dl; p=O.4). No 
pericardial effusions were detected by echo. No malignant or sustained ventricular 
arrhythmias were detected post procedure and all pts were discharged after 48h. PVC’s 
at 24h post-procedure were similar to baseline 49.2 x103 vs 29x103 (~~0.12). respec- 
tively.At 8 wks there was a trend to a decrease in PVC’s from baseline 10.3~10~ 
(p=O.OB). Late events included one uncomplicated NSTMI at 7 days. No deaths occured. 
Conclusiolr Immediate and short-term follow-up of pts recieveing BMNC injections 
revealed mild elevations in CRP and troponin I at 24 hours and one cardiac event. No 
malignant arrhythmias were detected post procedure and in follow-up. BMNC therapy in 
these high risk pts was safe in follow-up to 8 weeks. 
1176-177 The Coronary Sinus: A Safe and Effective Route for 
Percutaneous Myoblast Transplantation 
Camille Brass&t, Claire Carrion, Patrick Bruneval, Didier Heudes, Ketty Schwartz, 
Albert Hagi?ge, Jean-Thomas Vilquin. Emmanuel Messas, Michel Desnos, Antoine 
Lafont, Philippe Menasch(?, Hopital Europ&?n Georges Pompidou, Paris, France, lnstitut 
de Myologie, Paris, France 
The potential of autologous skeletal myoblast (SM) transplantation to improve function of 
Infracted myocardium has been previously documented using epicardial injections. In 
search for alternate, less invasive approach, we assessed the safety and feasibility of 
percutaneous SM transfer through the coronary sinus system. Two pigs and 4 sheep 
underwent transfemoral cathetetisation of the anterior interventricular vein using a dedi- 
cated catheter (TransAccess@, Transvascular, Menlo Park, CA) which incorporates a 
tipped-phase-array ultrasound probe for guidance and an extendable needle for myocar- 
dial access. Upon correct positioning, the needle was pulled forward to the puncture the 
venous wall and a mIcroInfusion catheter was advanced through it to inject the cell sus- 
pension. Cultured SM (2x108) were thus intramyocardially delivered in 4 staged sites 
along the catheter tract. Two hours later, the hearts were explanted and processed for 
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the amount of trapped cells and their viability. There were no acute complications (death, 
tamponada, ventricular perforation, arrhythmia). Preliminary in vitro testing of cell viability 
after passage through the catheter yielded a 86.6 +/- 2.5% (mean +/- SEM) rate which 
was highly pressure-dependent. Following explantation, clusters of SM could be hlstolog- 
ically identified by computerized assisted analysis in the anterior, apical and septal walls 
in the 6 hearts and represented 11 +/- 2.2% of the initial injectate. The viability of grafted 
SM retrieved from the transplanted area and assessed by a positive staining for CD 56 
averaged 3%. This percentage which might represent an underestimation due to injec- 
tion in non infracted myocardium, is still 10 fold higher than that previously observed after 
SM injections through an endovascular catheter. These preliminary data suggest that the 
CS route could represent a safe and effective mean of percutaneous SM intramyocardial 
transfer but improvements in delivery systems remain mandatory to reduce physical train 
during injections and consequently optimise cell survival. 
1176-197 Combination of a Direct Thrombin Inhibitor, Argatroban, 
and Glycoprotein Ilb/llla Inhibitor Is Effective and Safe 
in Patients Undergoing Percutaneous Coronary 
Intervention 
Ik-Kvuna Jan& Bruce E. Lewis, William H. Matthai. Neal S. Kleiman, Massachusetts 
General Hospital, Boston, MA, Baylor College of Medicine, Houston, TX 
Background: Argatroban, a small molecule direct thrombin inhibitor, has been shown to 
block clot bound thrombin more effectively than does unfractionated heparin. Argatroban 
has not been systematically tested in patients undergoing percutaneous coronary inter- 
vention (PCI) with concurrent glycoprotein (GP) Ilb/llla. 
Methods: In this multicenter. prospective, pilot study argatroban was administered in 
patients undergoing PCI at 250 mcglkg bolus followed by 15 mcglkglmin during the pro- 
cedure. Additional boluses of 150 mcgikg were given, if ACT did not reach the target 
range of 275-325 sec. GP Ilb/llla inhibitor was administered simultaneously. The primary 
efficacy endpoint was vascular death, myocardial infarction (Ml), or urgent revasculariza- 
tion at 30 days. The safety endpoint was in-hospital major bleeding. MI was defined as 
CKMB elevation more than 3 times the upper limit of normal or cardiac symptoms with 
supportive cardiac marker or EKG evidence. 
Results: A total of 101 patients were enrolled and completed the PCI procedure. There 
were 72 males and the mean age was 65 years. Abciximab was given to 99 patients and 
double bolus eptifibatide to 2 patients. 76 patients had one target lesion treated and the 
rest, two or more lesions. 96 patients were treated with stenting. Second and third 
boluses of argatroban were required in 22 and 7 patients, respectively. The target ACT 
was achieved in 94 patients. The primary efficacy endpoint occurred in 3 (3.0%) patients 
(no vascular death, 3 MIS and 2 urgent revascularizations). Two additlonal patients had 
cardtac symptoms and elevated troponin without significant CKMB elevation. There were 
2 major bleeding events (1 retroperitoneal, 1 groin hematoma). Conclusion:Argatroban 
!n combination with GP Ilb/llla inhibitors provides adequate anticoagulation with accept- 
able bleeding risk. These data suggest that further investigation of argatroban in patients 
undergoing PCI is warranted. 
1176-196 Unfractionated Heparin Increases Platelet-Monocyte 
Binding In Vitro and in Patients Undergoing 
Percutaneous Coronary Intervention 
Scott Hardinq, Debra H. Josephs. David E. Newby, Ian Dransfield, Chris Haslett, Keith A. 
A. Fox. Jaydeep Sarma, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom 
Background: Unfractionated heparin is currently considered to be the anticoagulant of 
choice in patients undergoing percutaneous coronary intervention (PCI). Unfractionated 
heparin may be associated with adverse platelet actwation. Platelet-monocyte aggrega- 
tion (PMA) is a sensitive marker of platelet activation and may mediate pro-inflammatory 
cytokine release, tissue factor expression and augmented adhesion molecule expres- 
sion. We compared the effects of unfractionated heparin, a low-molecular-weight-heparin 
(enoxaparin). and a direct thrombin inhibitor (lepirudin) on PMA in vitro. We also investi- 
gated the effects of unfractionated heparin on PMA in patients prior to PCI. 
Methods: Peripheral venous blood was collected from 16 healthy volunteers into sodium 
citrate alone or sodium citrate with unfractionated heparin (1 U/ml), enoxaparin (0.6 U/ml) 
or lepirudin (56~g/ml). Blood was also drawn into sodium citrate tubes from 14 patients 
immediately before and five minutes after administration of 100 U/kg of unfractionated 
hepann, prior to elective PCI. PMA was determined by 2.color flow-cytometric analysis. 
Results: In healthy volunteers, PMA was higher in blood anticoagulated with sodium cit- 
rate and unfractionated heparin (20.1 * 1.9%) compared to sodium citrate alone (16.2 + 
1.6%, pcO.001) or sodium citrate with enoxaparin (16.9 * 2.0%, pcO.01) or lepirudin 
(17.0 + 2.2%, p<O.Ol). There were no differences in PMA in blood anticoagulated with 
sodium citrate alone, sodium citrate and enoxaparm, or sodium citrate and lepirudin 
(p=ns). Administration of unfractlonatsd heparin to patients prior to PCI was also associ- 
ated with increased PMA (24.2 f 2.6% vs. 16.9 * 2.4%, p<O.Ol). 
Conclusions: In contrast to enoxaparin and kpirudin, unfractionated heparin increases 
PMA in vitro: an effect that was also demonstrable in patients receiving unfractionated 
heparin prior to PCI. Given that PMA is a sensitive measure of platelet activation and 
may have proinflammatory consequences, the use of alternative anticoagulant regimens 
may reduce PCI associated complications. 
1176-199 Safety and Efficacy of Subcutaneous Enoxaparin in 
Early Invasive Strategy of Unstable Angina 
Jean-Philippe Collet, Gilles Montalescot, Jean-Louis Golmard, M. Tanguy, Remi 
Choussat, Gerard Drobinski, Annick Ankri. Nicolas Vignolles, Daniel Thomas, Pitie 
SalpBtriBre, Paris, France 
Introduction : We have demonstrated previously that subcutaneous (s/c) enoxaparin 
(1 mglKg/lPh) given during at least 46 hours provided good anticoagulation and clinical 
results in non-ST elevation acute coronary syndromes (NSTE-ACS) patients undergoing 
percutaneous coronary intervention (PCI) within 6 hours of the last injection. We evalu- 
ated whether an early invasive (El) strategy with only 2 injections of sic enoxaparin was 
as good as a delayed invasive (DI) strategy with 3 injections or more. 
Methods and results : We compared NSTE-ACS patients who underwent PCI after 2 
injections of s/c enoxaparin (El. n=ll7) with those referred later on (DI, 5.9AO.2 s/c injec- 
tions. n=230). Anti-Xa at the time of catheterization, safety and major coronary events 
(death/Ml) were assessed at 30 days. Baseline characteristics were similar in the 2 
groups of patients. The period of medical stabilization was 20.5+1.0 hrs in the ‘“El” and 
69.2i3.0 hrs in the “DI” group, respectively (p<O.OOOl). The anti-Xa activity measured at 
the time of catheterization (0.92+0.04 U/mL vs 0.96+0.02 U/mL. p=O.25) and the injection 
to catheterization time (5.6kO.2 hrs. vs 5.2iO.l hrs, p=O.17) were similar in both groups. 
Patients of the “El” group were more frequently treated by Ilb/llla inhibitors and clopi- 
dogrel before PCI than patients of the “DI” group (56.1% vs 31.7%. pcO.0001 for GPllbl 
llla inhibitors and 66.4% vs 40.4% for clopidogrel pretreatment, p<O.OOOi, respectively). 
Bleeding rates were found to be equivalent between both groups (1.7% vs 4.6%, for “El” 
and “DI” strategies respectively, p=O.23, one-sided 95% Cl of 0.626). There was a non 
significant trend for less death or Ml at 30 days in the ‘“El” group compared to the “DI” 
group (4.3% vs 7.0%, respectively, p=O.32, one-sided 95% Cl of 1.536). 
Conclusion: In patients with NSTE-ACS, a rapid invasive strategy with only 2 s/c injec- 
tions of enoxaparin provides similar levels of anticoagulation and similar bleeding rates 
with a trend for less ischemic major events as a more prolonged “upstream” treatment 
with enoxaparin. 
1176-200 Assessment of Anticoagulation Using Activated 
Clotting Times in Patients Receiving Intravenous 
Enoxaparin During Percutaneous Coronary Intervention 
Mark Lawrence, Timothy Mixon, Donald Cross, Gregory Dehmer, Scott and White Clinic, 
Temple, TX 
Background: Low molecular weight heparins have many advantages over unfraction- 
ated heparin. They have been used safely during percutaneous coronary intervention 
(PCI) when given intravenously (IV) with and without glycoprotein 2bl3a receptor inhibi- 
tors. lnterventionalists have been reluctant to use this therapy because of the inability to 
monitor the anticoagulant effect of IV enoxaparin. We measured activated clotting time 
(ACT), before and after IV enoxaparin, to determine if anticoagulation could be assessed 
with this standard test. 
Methods: 45 consecutive patients undergoing PCI received either 0.75 mg!kg IV enox- 
aparin if they also received eptifibatide, or 1 mglkg IV enoxaparin if no eptifibatide was 
given. ACT was measured using the Hemochron device before and 5 minutes following 
IV enoxaparin administration. 
Resuks: After 0.75 mg/kg enoxaparin, mean ACT Increased from 132 _c 31 set to 207+ 
25 sec. (pcO.001). After 1 mg/kg enoxaparin. ACT increased from 121 -+ 26 set to 212+ 
32 ssc, (p<O.OOl). The mean increase in ACT value was 74 f 20 set (range 47 to 132) in 
the 0.75 mglkg group (n=36) and 92 + 26 set (range 32 to 120) in the 1 mg/kg group 
(n=9). None of the patients had transient abrupt closure, thrombus formation, major 
bleeding or required urgent revascularization. 
Conclusions: Intravenous enoxaparin at clinically relevant doses, increases ACT levels 
in patients undergoing PCI with and without eptifibatide. These data suggest that ACT 
may be useful in the measurement of enoxaparin anticoagulation. 
1176-201 A Randomized Comparison of Dalteparin Versus 
Unfractionated Heparin During Percutaneous Coronary 
Interventions 
Madhu K. Nataraian. Graham A. Turpie, Dominic L. Race. James L. Velianou, Shamlr R. 
Mehta, Rizwan Afzal. David R. Goodhart, Jeffrey S. Ginsberg, McMaster University, 
Hamilton, ON, Canada 
Background: Low molecular weight heparins are widely used in patients with coronary 
artery disease but experience with them during percutaneous coronary interventions 
(PCI) is limited. The purpose of this study was to compare the safety and efficacy of the 
low molecular weight heparin, dalteparin (Dalt.) to unfractionated heparin (UFH). 
Methods: A single-centre, randomized, double-blind study of Dalt. versus UFH in patients 
undergoing PCI was camed out. All patients undergoing planned or ad-hoc PCI (exclud- 
ing emergency PCI post-thrombolysis or for shock) were eligible. Randomization was 
